# Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction

Study · id `cardio:ct-nct07178145` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07178145](<https://clinicaltrials.gov/study/NCT07178145>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07178145

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 192 participants.

## Technical summary

Registry record NCT07178145. Non-randomized; no masking; primary purpose diagnostic. Start 2025-11-20 (actual); primary completion 2029-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 192 participants (planned count; ClinicalTrials.gov record NCT07178145, source copy `cardio:ctgov-nct07178145-2026-08-11`, retrieved 2026-10-26)
- Started: 2025-11-20 (actual) (ClinicalTrials.gov record NCT07178145, source copy `cardio:ctgov-nct07178145-2026-08-11`, retrieved 2026-10-26)
- Primary completion: 2029-09 (anticipated) (ClinicalTrials.gov record NCT07178145, source copy `cardio:ctgov-nct07178145-2026-08-11`, retrieved 2026-10-26)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07178145, source copy `cardio:ctgov-nct07178145-2026-08-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07178145, source copy `cardio:ctgov-nct07178145-2026-08-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07178145-2026-08-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
- Condition: Heart Failure Preserved Ejection Fraction
- Condition: Epicardial Adipose Tissue
- Intervention (Drug): GLP-1RA
- Lead sponsor: University of Virginia
- Lead sponsor class: OTHER
- Collaborator: National Institutes of Health (NIH)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry lists this organization as the lead sponsor: University of Virginia (`cardio:org-university-of-virginia`)
- Registry lists this organization as a collaborator: National Institutes of Health (`cardio:nih`)

## Provenance

Content hash: a5330d1add4928677c69fced27870c88fdf1fa1fcca21c2d2f1889610ca527ab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
